Literature DB >> 19843673

Sequence variant on 3q28 and urinary bladder cancer risk: findings from the Los Angeles-Shanghai bladder case-control study.

Mariana C Stern1, David Van Den Berg, Jian-Min Yuan, David V Conti, Manuela Gago-Dominguez, Malcolm C Pike, Yong-Bing Xiang, Yu-Tang Gao, Victoria K Cortessis.   

Abstract

Recently, the first genome-wide association study of bladder cancer identified an association of genome-wide significance between single nucleotide polymorphism (SNP) rs715021 and urinary bladder cancer risk among European individuals. This SNP is in a haplotype block in linkage disequilibrium with the TP63 gene. We investigated the role of this SNP among 1,042 cases and 1,123 controls among non-Latino whites in Los Angeles County, CA and among Chinese in Shanghai, China. We confirmed an association between the A allele and bladder cancer risk [log-additive per A allele odds ratios (OR), 1.24; and 95% confidence intervals (95% CI), 1.02-1.52; P = 0.032] in Los Angeles County and a similar association in Shanghai (log-additive per A allele OR, 1.21; 95% CI, 0.98-1.49; P = 0.080). These estimates did not differ by study site, smoking status, or gender. However, the effects were greater in older individuals. Analysis within non-Latino whites, for whom we had histologic results, revealed that this association was restricted to low-risk tumors (OR, 1.49; 95% CI, 1.17-1.92; P = 0.002) and absent among high-risk tumors (OR, 1.03; 95% CI, 0.80-1.33; P = 0.790; heterogeneity, P = 0.019). A positive association (OR, 1.56; 95% CI, 0.93-2.62; P = 0.089) was only observed among high-risk tumors from individuals older than 56 years old (interaction, P = 0.045). Our results suggest that a TP63 gene variant may increase susceptibility for the development of urinary bladder tumors with low risk of progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19843673      PMCID: PMC2783174          DOI: 10.1158/1055-9965.EPI-09-0492

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  14 in total

1.  Frequent alteration of p63 expression in human primary bladder carcinomas.

Authors:  B J Park; S J Lee; J I Kim; S J Lee; C H Lee; S G Chang; J H Park; S G Chi
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

Review 2.  p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress.

Authors:  F Murray-Zmijewski; D P Lane; J-C Bourdon
Journal:  Cell Death Differ       Date:  2006-06       Impact factor: 15.828

3.  p63 expression profiles in human normal and tumor tissues.

Authors:  Charles J Di Como; Marshall J Urist; Irina Babayan; Marija Drobnjak; Cyrus V Hedvat; Julie Teruya-Feldstein; Kamal Pohar; Axel Hoos; Carlos Cordon-Cardo
Journal:  Clin Cancer Res       Date:  2002-02       Impact factor: 12.531

4.  The Role of p63 and p73 in tumor formation and progression: coming of age toward clinical usefulness. Commentary re: F. Koga et al., Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin. Cancer Res., 9: 5501-5507, 2003, and P. Puig et al., p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder Cancer. Clin. Cancer Res., 9: 5642-5651, 2003.

Authors:  Ute M Moll
Journal:  Clin Cancer Res       Date:  2003-11-15       Impact factor: 12.531

5.  Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder.

Authors:  Fumitaka Koga; Satoru Kawakami; Yasuhisa Fujii; Kazutaka Saito; Yukihiro Ohtsuka; Aki Iwai; Noboru Ando; Touichiro Takizawa; Yukio Kageyama; Kazunori Kihara
Journal:  Clin Cancer Res       Date:  2003-11-15       Impact factor: 12.531

6.  p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer.

Authors:  Pere Puig; Paola Capodieci; Marija Drobnjak; David Verbel; Carol Prives; Carlos Cordon-Cardo; Charles J Di Como
Journal:  Clin Cancer Res       Date:  2003-11-15       Impact factor: 12.531

7.  Multiple loci with different cancer specificities within the 8q24 gene desert.

Authors:  Maya Ghoussaini; Honglin Song; Thibaud Koessler; Ali Amin Al Olama; Zsofia Kote-Jarai; Kristy E Driver; Karen A Pooley; Susan J Ramus; Susanne Krüger Kjaer; Estrid Hogdall; Richard A DiCioccio; Alice S Whittemore; Simon A Gayther; Graham G Giles; Michelle Guy; Stephen M Edwards; Jonathan Morrison; Jenny L Donovan; Freddie C Hamdy; David P Dearnaley; Audrey T Ardern-Jones; Amanda L Hall; Lynne T O'Brien; Beatrice N Gehr-Swain; Rosemary A Wilkinson; Paul M Brown; John L Hopper; David E Neal; Paul D P Pharoah; Bruce A J Ponder; Rosalind A Eeles; Douglas F Easton; Alison M Dunning
Journal:  J Natl Cancer Inst       Date:  2008-06-24       Impact factor: 13.506

8.  Sequence variant on 8q24 confers susceptibility to urinary bladder cancer.

Authors:  Lambertus A Kiemeney; Steinunn Thorlacius; Patrick Sulem; Frank Geller; Katja K H Aben; Simon N Stacey; Julius Gudmundsson; Margret Jakobsdottir; Jon T Bergthorsson; Asgeir Sigurdsson; Thorarinn Blondal; J Alfred Witjes; Sita H Vermeulen; Christina A Hulsbergen-van de Kaa; Dorine W Swinkels; Martine Ploeg; Erik B Cornel; Henk Vergunst; Thorgeir E Thorgeirsson; Daniel Gudbjartsson; Sigurjon A Gudjonsson; Gudmar Thorleifsson; Kari T Kristinsson; Magali Mouy; Steinunn Snorradottir; Donatella Placidi; Marcello Campagna; Cecilia Arici; Kvetoslava Koppova; Eugene Gurzau; Peter Rudnai; Eliane Kellen; Silvia Polidoro; Simonetta Guarrera; Carlotta Sacerdote; Manuel Sanchez; Berta Saez; Gabriel Valdivia; Charlotta Ryk; Petra de Verdier; Annika Lindblom; Klaus Golka; D Timothy Bishop; Margaret A Knowles; Sigfus Nikulasson; Vigdis Petursdottir; Eirikur Jonsson; Gudmundur Geirsson; Baldvin Kristjansson; Jose I Mayordomo; Gunnar Steineck; Stefano Porru; Frank Buntinx; Maurice P Zeegers; Tony Fletcher; Rajiv Kumar; Giuseppe Matullo; Paolo Vineis; Anne E Kiltie; Jeffrey R Gulcher; Unnur Thorsteinsdottir; Augustine Kong; Thorunn Rafnar; Kari Stefansson
Journal:  Nat Genet       Date:  2008-09-14       Impact factor: 38.330

9.  Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer.

Authors:  Jian-Min Yuan; Kenneth K Chan; Gerhard A Coetzee; J Esteban Castelao; Mary A Watson; Douglas A Bell; Renwei Wang; Mimi C Yu
Journal:  Carcinogenesis       Date:  2008-06-09       Impact factor: 4.944

10.  Impaired Delta Np63 expression associates with reduced beta-catenin and aggressive phenotypes of urothelial neoplasms.

Authors:  F Koga; S Kawakami; J Kumagai; T Takizawa; N Ando; G Arai; Y Kageyama; K Kihara
Journal:  Br J Cancer       Date:  2003-03-10       Impact factor: 7.640

View more
  4 in total

1.  Genetic variations on chromosomes 5p15 and 15q25 and bladder cancer risk: findings from the Los Angeles-Shanghai bladder case-control study.

Authors:  Manuela Gago-Dominguez; Xuejuan Jiang; David V Conti; Jose Esteban Castelao; Mariana C Stern; Victoria K Cortessis; Malcolm C Pike; Yong-Bing Xiang; Yu-Tang Gao; Jian-Min Yuan; David J Van Den Berg
Journal:  Carcinogenesis       Date:  2010-11-15       Impact factor: 4.944

2.  Genetic susceptibility to bladder cancer risk and outcome.

Authors:  Jian Gu; Xifeng Wu
Journal:  Per Med       Date:  2011-05       Impact factor: 2.512

3.  The Functional Haplotypes of CHRM3 Modulate mRNA Expression and Associate with Bladder Cancer among a Chinese Han Population in Kaohsiung City.

Authors:  Chiang-Ting Wang; Tsung-Ming Chen; Chien-Tai Mei; Chun-Feng Chang; Li-Lian Liu; Kuo-Hsun Chiu; Tsung-Meng Wu; Yu-Ching Lan; Wen-Sheng Liu; Ya-Huey Chen; Yi-Mei Joy Lin
Journal:  Biomed Res Int       Date:  2016-12-07       Impact factor: 3.411

Review 4.  Systematic Review: Genetic Associations for Prognostic Factors of Urinary Bladder Cancer.

Authors:  Nadezda Lipunova; Anke Wesselius; Kar K Cheng; Frederik J van Schooten; Jean-Baptiste Cazier; Richard T Bryan; Maurice P Zeegers
Journal:  Biomark Cancer       Date:  2019-12-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.